Amplify Treatments, Testing and Advancements ETF
GERM
GERM was delisted on the 5th of September, 2024.
24 hedge funds and large institutions have $6M invested in Amplify Treatments, Testing and Advancements ETF in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
26% more capital invested
Capital invested by funds: $4.74M → $6M (+$1.26M)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
9% more funds holding
Funds holding: 22 → 24 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$601K |
| 2 |
Jane Street
New York
|
+$267K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$225K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$198K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$124K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IWM
IHT Wealth Management
Chicago,
Illinois
|
-$237K |
| 2 |
LPL Financial
San Diego,
California
|
-$173K |
| 3 |
GBWM
Granite Bay Wealth Management
Portsmouth,
New Hampshire
|
-$13.1K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$9.08K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$5.63K |
GERM Hedge Fund Activity: Q4 2022 in Review
24 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q4 2022, worth a combined $6M — up 26% from $4.74M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new GERM positions and 1 closed out — a net gain of 3 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $601K. The largest seller was IHT Wealth Management, exiting entirely with an estimated $237K sold.
- 24 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q4 2022, up from 22 in Q3 2022.
- Funds reported $6M of Amplify Treatments, Testing and Advancements ETF stock for Q4 2022, up 26% quarter-over-quarter.
- 4 funds opened new Amplify Treatments, Testing and Advancements ETF positions in Q4 2022 and 1 closed out, a net change of +3 holders.
- The largest Amplify Treatments, Testing and Advancements ETF buyer in Q4 2022 was Goldman Sachs, an estimated $601K added.
- The largest Amplify Treatments, Testing and Advancements ETF seller in Q4 2022 was IHT Wealth Management, an estimated $237K sold.
Based on aggregated 13F filings for Q4 2022.